Advanced Enzyme Technologies Limited (ADVENZYMES)
Micro CapPharma stocks · Micro cap · NSE
Advanced Enzyme Technologies Ltd. is a research-driven global leader in manufacturing enzymes and probiotics. It provides eco-safe solutions for human & animal nutrition, baking, fruit & vegetable processing, brewing, grain processing, protein modification, dairy, specialty applications, and textile processing, aiming to replace chemicals with enzymatic solutions.
One read, four checks
75+ is strong, 60-74 is usable, 45-59 is mixed, and below 45 needs caution. These are research lenses, not buy/sell instructions.
Weak fundamentals, management trust is supportive, price trend argues for patience, and recent execution is consistent.
Fundamental lens: valuation, quality, growth, balance sheet, and cash flow.
low confidence · 0/0 claims checked
Timing lens: price trend and sector relative strength.
Rolling lens: recent quarterly delivery, not the latest single-result score.
Quarter ended 30 Jun 2026
Bad · 0/100PAT -3% YoY · margin compression · Rev +2% YoY
| Metric | This quarter | YoY | QoQ |
|---|---|---|---|
| Revenue | ₹190 Cr | +2.1% | -6.4% |
| EBITDA | ₹51 Cr | -8.9% | -19.0% |
| Operating margin | 27.0% | -300 bps | -400 bps |
| PAT | ₹39 Cr | -2.5% | -13.3% |
| PAT margin | 20.5% | -98 bps | -164 bps |
NDF means not disclosed in the current structured filing feed. It is intentionally not treated as zero.
Business & thesis
Growth engines, tailwinds/headwinds, and risk radar from management commentary
Business & thesis
Growth engines, tailwinds/headwinds, and risk radar from management commentary
Where growth can come from, and what can break the case
ADVENZYMES reported strong Q4 FY26 results with Revenue up 22% YoY to 2,034 mn, EBITDA up 39% YoY to 632 mn, and PAT up 69% YoY to 453 mn. For FY26, Revenue grew 17% YoY to 7,458 mn, EBITDA 18% YoY to 2,291 mn, and PAT 30% YoY to 1,736 mn, driven by broad-based segment growth.
The company delivered robust financial performance in Q4 and FY26, with significant YoY and QoQ growth in revenue and profitability. Strategic focus on R&D, geographical expansion, and inorganic growth, coupled with strong segment performance, supports the investment thesis.
Revenue by Segment (Q4 FY26)
Latest issuer-disclosed distribution across 4 reported categories.
Human Nutrition Segment
Contributed 63% to Q4 FY26 revenue, grew 24% YoY to 1,281 mn, and 33% QoQ.
Animal Nutrition Segment
Grew 19% YoY in Q4 FY26 to 250 mn; 25% YTD in FY26 to 946 mn.
Industrial Bio-Processing (Food)
Food business grew 20% YoY in Q4 FY26 to 276 mn.
Specialized Manufacturing Segment
Grew 17% YoY in Q4 FY26 to 180 mn; 23% YTD in FY26 to 662 mn.
Manufacturing Units
Operates 9 manufacturing units (8 in India, 1 in USA).
Fermentation Capacity
Total fermentation capacity of 500 m3.
Solar Power Plant
Successfully commissioned a 510kW solar power plant.
Global Enzymes Market Growth
Expected to grow at a CAGR of 14.12% from CY 2024-29.
Global Probiotics Market Growth
Expected to grow at a CAGR of 7.80% till 2029.
Shift to Eco-friendly Solutions
Company's mission to replace traditionally used chemicals with eco-friendly enzymatic solutions.
Americas Revenue Decline
Revenue from Americas de-grew 11% YoY in Q4 FY26 and 7% YTD in FY26.
Europe Revenue Decline
Revenue from Europe de-grew 7% YoY in Q4 FY26.
Industrial Bio-Processing (Non-Food) Stagnation
Non-Food business de-grew 1% YoY in Q4 FY26 and remained flat YTD in FY26.
Management accountability
What management said, and what results must prove
Management accountability
What management said, and what results must prove
What management said, and what results must prove
Issuer guidance and extracted claims are tracked against later reported outcomes. Treat these as management statements, not IndiaPulse forecasts.
Q4 FY26 results show strong YoY growth across revenue and profitability, indicating robust performance compared to the previous year. QoQ growth also shows sequential momentum, especially in revenue and EBITDA, suggesting continued operational strength.
EBITDA Margin
Q4 FY26: 31%; FY26: 31%
PAT Margin
Q4 FY26: 22%; FY26: 23%
Domestic Revenue Growth (India)
Q4 FY26: +51% YoY to 1,061 mn; FY26: +28% YoY to 3,727 mn
Americas Revenue Growth
Q4 FY26: -11% YoY to 573 mn; FY26: -7% YoY to 2,192 mn
Continued R&D Investment
Focus on identifying product gaps and developing new enzymes, probiotics & solutions.
Broaden Geographical Presence
Build strategic partnerships in key markets for focus segments.
Inorganic Expansion Strategy
Acquisition of key technologies, competencies, skill-sets, client relationships & businesses.
Bio-Catalysis for API Manufacturers
Developing enzymatic solutions for API manufacturers; products under advanced trial stages.
Numbers and claims to verify in the next filings
| Checkpoint | Current evidence | What to verify next |
|---|---|---|
| Americas Revenue Growth | -11% YoY in Q4 FY26. | Reversal of de-growth trend and return to positive growth. |
| Industrial Bio-Processing (Non-Food) Growth | -1% YoY in Q4 FY26. | Improvement in growth trajectory and contribution to segment. |
| API Bio-catalysis Commercialization | Products under advanced trial stages. | Successful commercialization and revenue contribution from API bio-catalysis. |
| New Probiotics Product Launches | Plans to introduce more probiotics products. | Specific product launches and market acceptance in human and animal nutrition. |
Verification checkpoints are IndiaPulse research interpretation, not investment advice.
Trend score and candlestick chart
39Bearishfull bear SMA stack · SMA20 -6.6% / mo · MACD + · sector +2.2pp vs Nifty (3M)
Technical chart
ADVENZYMESdaily · 1Y · AUTO-0.7%Daily technical trend read
Bearish setupTrend is weak — long-term trend down. RSI 38.
- Price < SMA20 < SMA50 < SMA200 — full bearish stack.
- Recent death cross (SMA50 crossed below SMA200).
- SMA20 falling (~7.1% over last month) — short-term momentum negative.
- RSI(14) at 38 — falling, no extreme reading.
- MACD above signal, histogram expanding — bullish momentum building.
- 30% off 52W high · 16% above 52W low.
Mechanical read from the price + indicator series above. Not a recommendation — technical setups can reverse without warning, especially around earnings and macro events.
Valuation & score drivers
U-Score 42 · WATCHLIST · pillar breakdown, sector model, fair-value anchor
Valuation & score drivers
U-Score 42 · WATCHLIST · pillar breakdown, sector model, fair-value anchor
Fundamental score breakdown
WATCHLISTWhy this score?
Top U-Score contributors and drags from the latest stored fundamentals.
Positive drivers
- Piotroski is strong at 8/9.
- Balance sheet contributes 12/15 to the score.
- Cash flow contributes 8/10 to the score.
Main drags
- Fair-value margin of safety is negative at -145.4%.
- Quality is weaker at 2/20; verify the latest quarterly trend.
- Valuation is weaker at 6/30; verify the latest quarterly trend.
Healthcare valuation: PE/EVEBITDA with regulatory and pipeline checks
Healthcare valuation needs both earnings quality and regulatory/pipeline context.
Stored run vs live recompute
This shows the stored score trend when snapshots exist, and also compares the latest stored nightly score with a live recompute from current fundamentals and price.
Score history
12 stored score snapshots. Latest stored move: +0 points.
Factor attribution
Modelled fair value
Trust score
Does management behaviour match later outcomes? Claim delivery, forensic breakdown, evidence depth
Trust score
Does management behaviour match later outcomes? Claim delivery, forensic breakdown, evidence depth
Trust asks: does management behaviour match later outcomes? Higher is better, but confidence and evidence depth matter as much as the number.
Healthy Trust: Claim history is still being built. It ranks around the 90th percentile of the scored universe and 87th percentile within Pharma. No major sub-score weakness stands out.
High Trust Lite: Promoter pledge is zero.
Generally investable credibility. Look for weak sub-scores before increasing position size.
overall median 67 · Pharma: 87th pctile, median 70 · Micro: 81st pctile, median 73
176 documents have extracted text, but claim history is not strong enough yet.
0 claims extracted · No contradicted claim yet
How to read this Trust Score
Healthy Trust · low confidenceRead Trust alongside U-Score, result consistency, and technical trend. A cheap stock with weak Trust needs a larger margin of safety; a high Trust score does not make an expensive stock attractive by itself.
Forensic breakdown
Read low sub-scores as due-diligence warnings, not automatic sell signals.
Trust positives
- ▸Promoter pledge is zero.
- ▸FCF yield is positive at 2.6%.
- ▸11 years of positive FCF.
- ▸Debt/equity is 0.02.
Trust risks
- ▸No major Trust Lite risk flags.
Trust Lite uses financial behaviour only. Prefer claim-tested Trust when enough concall claims have later outcomes.
Financials
Full fundamentals table and 10-year revenue / profit / ROE history
Financials
Full fundamentals table and 10-year revenue / profit / ROE history
Fundamentals
Valuation
- P/E
- 20.80
- P/B
- 2.01
- EV/EBITDA
- 12.56
- Market Cap
- 3283.00Cr
Profitability
- ROE
- 10.20%
- ROCE
- 14.00%
- ROA
- 9.38%
- Dividend Y
- 1.82%
Growth (CAGR)
- Revenue 5Y
- 8.00%
- EPS 5Y
- 1.00%
- Revenue 3Y
- 11.00%
- EPS 3Y
- 12.00%
Balance Sheet
- Debt/Equity
- 0.02
- Interest Coverage
- 112.00×
- Altman Z
- 8.36
- Book Value
- 146.00
Cash Flow
- FCF Yield
- 2.59%
- FCF Positive Y
- 11/5
- OCF
- 157.00 Cr
- EPS TTM
- 14.82
Shareholding
- Promoter Hold
- 43.25%
- Promoter Pledge
- 0.00%
- Momentum 52W
- 24%
Financial History
Updated 5/9/2026
Revenue
₹ CrNet Profit
₹ CrReturn on Equity
%Peers
Business-comparable names in Pharma, ranked by similarity
Peers
Business-comparable names in Pharma, ranked by similarity
Peers
Business-comparable peers in Pharma — ranked by industry, sub-sector, theme-tag overlap, market cap, and U-Score similarity. Green cells mark the best available peer metric in this table.